CA-INSEEGO-CORP
26.7.2022 13:03:16 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG) announced today that the Inseego Wavemaker™ FX2000 5G indoor router is now being sold to customers on the Three Sweden network. Three Sweden is part of Three Group Europe, which includes networks in Austria, Denmark, Italy, Ireland, Sweden and the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005524/en/
The award-winning FX2000 fixed wireless access (FWA) router can deliver gigabit speeds for fast and reliable internet access, along with Wi-Fi 6 for up to 30 devices, making it ideal for remote work, streaming and gaming. With its small, elegant design and simple setup, it fits into any environment, from home offices to summer cottages.
“We’re proud to provide this fixed wireless access solution to Three Sweden and their customers,” said Simon Rayne, senior vice president and managing director, UK, EMEA, and Asia-Pacific for Inseego. “This is the first commercial launch of our FX2000 with a European carrier, and we look forward to many more. Our 5G solutions are changing the way millions of people stay connected at home, in the office, and on the move.”
“This router is an excellent choice for our customers who want the speed and simplicity of 5G home internet,” said Rune Pedersen, CCO Consumer Market at Three Sweden. “Combined with our unlimited 3Bredband Max, it’s an easy, affordable way to plug into the power of new 5G experiences.”
Speed, simplicity and flexibility: With its small footprint and low profile, the FX2000 fits into any setting. It can be placed on a tabletop or desktop and moved easily when relocating to a new home or office.
Easy setup and management: The FX2000 can be set up by anyone (no service technician needed) in just a few minutes. The Inseego Mobile smartphone app makes it easy to choose the best placement and manage the FX2000 with user-friendly control settings.
Best-in-class performance: With Inseego’s industry-leading antenna and RF technology, the FX2000 can deliver peak 5G speeds over 1 Gbps (depending on network coverage), along with fallback to Cat 22 LTE. Sustained high throughput and low latency 5G connections are ideal for applications such as video conferencing, streaming media, AR/VR and cloud computing. The FX2000 supports dual-band Wi-Fi 6 for up to 30 connected devices, as well as an ethernet LAN port and USB port, to connect up to 32 devices simultaneously. The ethernet LAN port can also be connected to other routing devices.
Enterprise-grade security: Designed and developed in the U.S. with multiple layers of advanced security, the FX2000 safeguards data with advanced encryption, hacker prevention, password protection, OpenVPN, guest Wi-Fi network and more. Robust authentication protects against cyber threats and allows customers to connect with confidence.
To learn more about Inseego 5G products and solutions, please go to inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Inseego’s mobile broadband, fixed wireless access (FWA) solutions and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of innovative products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service provider, enterprise, and government entities worldwide. www.inseego.com #Putting5GtoWork
Inseego 5G FX2000 chipset: Qualcomm® Snapdragon® X55 5G Modem-RF System.
©2022. Inseego Corp. All rights reserved. The Inseego name and logo name and logo are registered trademarks and Wavemaker is a trademark of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005524/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom